Corcept Therapeutics CORT 深 滬
等待開盤 10-31 09:30:00 美东时间
72.26
+0.210
+0.29%
華盛通- 最 高73.985
- 今 開72.21
- 成交量 57.76万股
- 最 低 71.59
- 昨 收 72.05
- 總市值 75.87亿
- 52周最高 117.33
- 市盈率 靜 58.69
- 換手率 0.55%
- 52周最低 49.00
- 委 比 -89.05%
- 總股本 1.05亿
- 歷史最高 117.33
- 量 比 1.01
- 振 幅 3.32%
- 歷史最低 1.27
- 每 手 1
- 風險率 9.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多清晰视界等你来战！EVNIA弈威携旗下旗舰电竞显示器亮相合肥师范
【ZOL中关村在线原创新闻】10月26日，“我们学校潮好玩第二季”落地合肥师范学院。知名显示器品牌飞利浦，带来了旗下的EVNIA弈威QD OLED双核电竞显示器...
10-25 06:51
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock
Corcept Therapeutics (NASDAQ:CORT) underwent analysis by 6 analysts in the last...
10-20 22:03
Reported Sunday, Corcept Highlights ROSELLA Late-Breaker: Relacorilant Plus Nab-Paclitaxel Improves PFS And OS In Platinum-Resistant Ovarian Cancer
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker
10-20 15:37
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $145 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintains $145 price target.
10-10 19:06
Corcept Therapeutics Board Member Resigns, Continues as Consultant
An announcement from Corcept Therapeutics ( ($CORT) ) is now available. On Octo...
10-07 04:59
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Corcept Therapeutics To Present New Data From Pivotal Phase 3 ROSELLA Trial Of Relacorilant Plus Nab-Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer At 2025 ESMO
Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by
09-23 02:31
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
Corcept's ovarian cancer treatment under FDA review
Corcept Therapeutics (NASDAQ:CORT) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment of platinum-resistant ovarian cancer. The agency h...
09-10 20:51
